Cellistic

Cellistic company information, Employees & Contact Information

Explore related pages

Related company profiles:

Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit www.cellistic.com.

Company Details

Employees
89
Address
Rue Edouard Belin 2, Mont-Saint-Guibert,1435,belgium
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Technician jobs.
HQ
Mont-Saint-Guibert
Looking for a particular Cellistic employee's phone or email?

Cellistic Questions

News

Cellistic Launches Allo Chassis : Ready-to-use, immune-cloaked iPSC Cell Lines facilitating cost-effective cell therapy development - Business Wire

Cellistic Launches Allo Chassis : Ready-to-use, immune-cloaked iPSC Cell Lines facilitating cost-effective cell therapy development Business Wire

Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions - Business Wire

Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions Business Wire

The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - BioInformant

The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD BioInformant

Induced Pluripotent Stem Cells Market Size to Hit USD 5.12 Billion by 2034 - Precedence Research

Induced Pluripotent Stem Cells Market Size to Hit USD 5.12 Billion by 2034 Precedence Research

Cellistic Reveals Groundbreaking iPSC-based Platforms to Accelerate Off-the-shelf Allogeneic Cell Therapy Development and Manufacturing - Business Wire

Cellistic Reveals Groundbreaking iPSC-based Platforms to Accelerate Off-the-shelf Allogeneic Cell Therapy Development and Manufacturing Business Wire

Ncardia Launches Cellistic™, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today - BioInformant

Ncardia Launches Cellistic™, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today BioInformant

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Business Wire

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction Business Wire

Top Cellistic Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant